IDT Australia Limited · ASX:IDT
IDT Australia — Shareholder Meeting (November 2026)
14 slides from IDT Australia's shareholder meeting presentation, Nov 18, 2026
Slide 1: From Turnaround to Growth
rsonal use only ANNUAL GENERAL MEETING · 2026 From Turnaround to Growth November 2026 Advanced Manufacturing for Breakthrough Medicines ASX: IDT
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It This presentation may contain forward-looking statements, guidance, forecasts, estimates, rsonal use only contains general background information only which is current at the d
Slide 3: Building on the Momentum
Building on the Momentum From turnaround to growth FY26 RESULTS HIGHLIGHTS FY27 GUIDANCE rsonal use only REVENUE, 3 VERTICALS The Turnaround REVENUE, 3 VERTICALS EBITDA loss narrowed 85% FY26 FY27 –$6.3M ▲ 13% - 19% $16.8M $19.0M - $20.0M ▲ 16.5% YoY EBITDA –$0.9M FY26: $16.8M | FY25: $14.4M FY26 FY
Slide 4: Business Growth Drivers
Business Growth Drivers Why we are more confident than 12 months ago rsonal use only 1 2 3 4 5-Year Return to Profitability Radiopharmaceutical ~$7M Plant Upgrade $50M Revenue Pathway Contract Signed Positive EBITDA forecast from New contract from existing Modernising plant and Clear strategy to ach
Slide 5: Objectives of Business Reset Strategy
Objectives of Business Reset Strategy Why we reset the business rsonal use only Sustainable Growth Reduce Revenue Volatility Focus on operating profits, margins and cost Building a bank/backlog of work to fill gaps when control instead of revenue growth at any cost client contracts get unexpectedly
Slide 6: End-to-End Manufacturing Advantage
End-to-End Manufacturing Advantage One of the few Australian CDMOs that can support customers from API through to finished -dose rsonal use only Active Pharmaceutical Solid Oral Manufacturing Sterile Manufacturing Ingredient (API) Full-year revenue up 29% to $5.4M Full-year revenue up 52% to $5.5M F
Slide 7: Multiple Markets Supporting Growth
Multiple Markets Supporting Growth IDT’s $50M target reflects <0.038% of serviceable addressable market (SAM) rsonal use only Total SAM IDT is a specialist, agile CDMO focused on complex Small-Molecule API, and Sterile & Non-Sterile manufacturing — delivering the agility and responsiveness required
Slide 8: Upgrade Program Progressing to Plan
Upgrade Program Progressing to Plan ~$7M business investment is fully funded New Sterile Manufacturing Line Solid oral dose upgrade rsonal use only Isolator Technology — the global gold standard for Grade A aseptic fill-finish Tablet Press, Coating, Solids Handling & Complete Bottle Line • Enables c
Slide 9: Sterile Manufacturing: The Largest Growth Opportunity
Sterile Manufacturing: The Largest Growth Opportunity Competitive advantage as end -to-end specialist & agile CDMO rsonal use only APAC is fastest growing region at 12.3% CAGR (vs. ROW New sterile manufacturing line: 11.2%) Isolator-based aseptic fill-finish system Strong pricing power due to lack o
Slide 10: Pathway to $50M Revenue
Pathway to $50M Revenue Why we believe the target is achievable Strategic positioning rsonal use only Positioning 01 Specialist in complex small-molecule API and sterile & non-sterile manufacturing — an agile solution for emerging biotech and pharma. Customer Expansion Existing customer expansion 02
Slide 11: Outlook and Highlights
Outlook and Highlights Return to sustained profitability from FY27 rsonal use only From Turnaround to Growth Improving Earnings Quality • Improved operating leverage • Increased level of repeat & follow-on work via end-to-end services • FY27 Forecast Revenue – $19.0M - $20.0M (up 19%-25%) • Deepenin
Slide 12: Board of Directors
Board of Directors Experienced board and leadership team rsonal use only An experienced and accomplished professional in the health industry with over 17 years' board experience Mark Simari across a diverse range of organisations. Former managing director and co-founder of Paragon Care (2008– Execut
Slide 13: Investor & Media Enquiries
rsonal use only INVESTOR & MEDIA ENQUIRIES Brendon Lau brendon@vantagepointpartners.com.au +61 409 341 613 Advanced Manufacturing for Breakthrough Medicines
Slide 14: References & Definitions
Appendix References & Definitions rsonal use only REFERENCES DEFINITIONS 1 Mordor Intelligence — Active Pharmaceutical Ingredients (API) market Total Addressable Market mordorintelligence.com/industry-reports/global-active-pharmaceutical-ingredients-api-market TAM Total market demand — the maximum r